MLAB vs NOVT

For growth investors, Mesa Laboratories, Inc.

(MLAB) is the stronger pick with 11. 5% revenue growth year-over-year, versus 3. 3% for Novanta Inc. (NOVT). Novanta Inc. (NOVT) offers the better valuation at 92. 7x trailing P/E (38. 2x forward), making it the more compelling value choice. Analysts rate Novanta Inc. (NOVT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Mesa Laboratories, Inc.

is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Novanta Inc.

(NOVT) delivered a total return of +5. 7%, compared to -56. 5% for Mesa Laboratories, Inc. (MLAB). Over 10 years, the gap is even starker: NOVT returned +853. 7% versus MLAB's +4. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mesa Laboratories, Inc.

(MLAB) is the lower-risk stock at 1. 78β versus Novanta Inc. 's 2. 02β — meaning NOVT is approximately 13% more volatile than MLAB relative to the S&P 500. On balance sheet safety, Novanta Inc. (NOVT) carries a lower debt/equity ratio of 26% versus 114% for Mesa Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Mesa Laboratories, Inc.

(MLAB) is pulling ahead at 11. 5% versus 3. 3% for Novanta Inc. (NOVT). On earnings-per-share growth, the picture is similar: Mesa Laboratories, Inc. grew EPS 99. 2% year-over-year, compared to -16. 9% for Novanta Inc.. Over a 3-year CAGR, MLAB leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novanta Inc.

(NOVT) is the more profitable company, earning 5. 5% net margin versus -0. 8% for Mesa Laboratories, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NOVT leads at 11. 9% versus 6. 8% for MLAB. At the gross margin level — before operating expenses — MLAB leads at 62. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Mesa Laboratories, Inc.

(MLAB) trades at 11. 7x forward P/E versus 38. 2x for Novanta Inc. — 26. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NOVT: 10. 1% to $150. 00.

In this comparison, MLAB (0.

6% yield) pays a dividend. NOVT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mesa Laboratories, Inc.

(MLAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 6% yield). Novanta Inc. (NOVT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MLAB: +4. 5%, NOVT: +853. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

MLAB pays a dividend while NOVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.